PMC7292976_01
18F-FDG PET/CT scan showing the difference in SUV maximum for lesion located in C6 at the moment of diagnosis (a) vs SUV maximum for same location after 3-cycle of Lenvatinib oral treatment (b). The decrease was quantified in 39.5%.
CRIONM2020-8679149.001.jpg
PMC7292976_01_CRIONM2020-8679149.001.jpg
fig1
SUV from 13.4 to 8.1 (Figure 1), which represents a 39.5% of decrease. Serum thyroglobulin levels also decreased from 49105 ng/ml to 2500 ng/ml in this period.